Selenoinosine API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Selenoinosine | CAS No: 40093-99-0 | GMP-certified suppliers
A medication that serves as an experimental selenium compound potentially involved in redox-related disorders, requiring stringent quality control for research and development applications.
Therapeutic categories
Product Snapshot
- Selenoinosine is an oral small molecule formulation
- It is primarily investigated for potential applications in metabolic and neurological disorders
- The compound is currently in experimental stages and has not yet received FDA or EMA approval
Clinical Overview
Due to the lack of available pharmacodynamic and mechanistic data, the precise biological activity and mechanism of action of selenoinosine have not been characterized in the literature. As a selenium compound, it may participate in redox processes or enzyme interactions typical of selenium derivatives; however, specific pharmacological effects require further investigation.
Key absorption, distribution, metabolism, and excretion (ADME) parameters have not been reported. Without such data, assessments of bioavailability, metabolic pathways, elimination half-life, and potential drug interactions cannot be definitively stated.
Safety and toxicity profiles for selenoinosine have not been documented in published studies. Selenium compounds can vary widely in toxicity, depending on chemical form and dosage, which underscores the importance of comprehensive toxicological evaluations during the experimental phase.
There are no notable brand names or commercial uses associated with selenoinosine, reflecting its current status as a research-stage molecule rather than a marketed pharmaceutical.
For API sourcing and quality considerations, procurement of selenoinosine should adhere to stringent quality standards due to the experimental status and potential toxicity associated with selenium compounds. Suppliers must provide comprehensive analytical documentation including purity, residual solvents, heavy metal content, and certificate of analysis. Regulatory compliance with Good Manufacturing Practice (GMP) guidelines is essential to ensure batch-to-batch consistency for research and development purposes.
Identification & chemistry
| Generic name | Selenoinosine |
|---|---|
| Molecule type | Small molecule |
| CAS | 40093-99-0 |
| DrugBank ID | DB02753 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| Nucleoside deoxyribosyltransferase-I | Lactobacillus helveticus |
Formulation & handling
- Selenoinosine is a small molecule solid with high aqueous solubility, favoring oral formulation development. Its low LogP value indicates hydrophilic properties suitable for immediate-release dosage forms. Stability considerations should focus on protecting the compound from moisture due to its solid state.
Regulatory status
Selenoinosine is a type of Other Antiretrovirals
The category of Other Antiretrovirals falls under the broad umbrella of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the treatment of retroviral infections, including HIV. Other Antiretrovirals encompass a range of compounds that target various stages of the retroviral life cycle and provide alternative therapeutic options.
These APIs exhibit potent antiretroviral activity and are designed to combat drug-resistant strains of the virus, enhancing treatment efficacy. They work by inhibiting key enzymes involved in viral replication or by blocking viral entry into host cells.
One notable subcategory within Other Antiretrovirals is fusion inhibitors. These APIs prevent the fusion of the viral envelope with the host cell membrane, thereby inhibiting viral entry and subsequent infection. They target the viral protein gp41, which is crucial for fusion.
Another subcategory is integrase inhibitors, which hinder the action of the viral enzyme integrase. By doing so, they prevent the integration of viral DNA into the host cell genome, thus impeding viral replication and propagation.
Additionally, maturation inhibitors are included in this subcategory. These APIs interfere with the final stages of viral assembly and maturation, disrupting the production of infectious viral particles.
By expanding the repertoire of available antiretroviral options, Other Antiretrovirals play a vital role in the management of retroviral infections, especially when other treatment regimens have failed or become ineffective. Their development and utilization contribute to the advancement of HIV therapy and ultimately improve patient outcomes.
Selenoinosine (Other Antiretrovirals), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
